IL-25 blockade inhibits metastasis in breast cancer. Inhibition of IL-25 resulted in decreased type 2 T cells and macrophages in the primary tumor microenvironments, both reported to enhance breast tumor invasion and subsequent metastasis to the lung. PubMed, Protein Cell, 2017 Mar;8(3):191-201. (Also see Cancer) and Interleukins)
Associations between specific autoimmune diseases and subsequent dementia: retrospective record–linkage cohort study, UK. The associations with vascular dementia may be one component of a broader association between autoimmune diseases and vascular damage and clinicians should be aware of the possible coexistence of autoimmune disease and dementia in individuals. PubMed, J Epidemiol Community Health, 03/01/2017. (Also see Autoimmunity)
Elevated serum autoantibodies against co–inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new–onset systemic lupus erythematosus (SLE) patients. The current study indicates, for the first time, that the serum levels of co–inhibitor autoantibodies against PD-1 are elevated in new–onset SLE patients and are associated with disease activity in SLE. PubMed, Arthritis Res Ther, 2017 Mar 9;19(1):52. (Also see Antibodies in Lupus)
Immunotherapy for Type 1 diabetes. Stem cell therapies achieved thus this far the most promising results, while immune ablation and standard immunosuppressants did not maintain the premises of preclinical results. PubMed, J Endocrinol Invest, 03/04/2017. (Also see Research on Diabetes)
Hashimoto's thyroiditis (HT): Relative recurrence risk ratio and implications for screening of first degree relatives. Relatives of HT patients have a 9 fold increased risk for developing HT as compared to the general population and the risk of developing HT exceeds that of the general population at 20 years in females and 27 years in males. PubMed, Clin Endocrinol (Oxf), 03/08/2017. (Also see Hashimoto's Thyroiditis)
Quality of life (QoL) in patients with (APS) antiphospholipid syndrome is related to disease burden and anticoagulant therapy. Health related QoL in primary APS was related to burden of the disease specifically at the vascular peripheral area and use of anticoagulants. PubMed, Int J Rheum Dis, 03/06/2017. (Also see Antiphospholipid Syndrome)
Y-27632, a Rho–associated protein kinase inhibitor, inhibits systemic lupus erythematosus. The findings showed that the inhibition of rho-associated, coiled–coil–containing protein kinase 1(ROCK) was beneficial for the prevention of systemic lupus erythematosus, which possibly by suppressing NF-?B activation. PubMed, Biomed Pharmacother, 2017 Apr;88:359-366. (Also see Interleukins and Research on Systemic Lupus Erythematosus)
Painful After–Sensations (PAS) in Fibromyalgia are Linked to Catastrophizing and Differences in Brain Response in the Medial Temporal Lobe (MTL). These results suggest that the MTL plays a role in PAS in FM patients. PubMed, J Pain, 03/11/2017. (Also see Fibromyalgia)
Biosimilars: implications for rheumatoid arthritis therapy. Five TNF inhibitor biosimilars have now been approved, and many other biosimilars to treat rheumatoid arthritis and other inflammatory diseases are in development. PubMed, Curr Opin Rheumatol, 03/16/2017. (Also see Biologic Agents and Treatments for Rheumatoid Arthritis)
Case Report: Diagnosis of autoimmune pancreatitis (AIP) with cholesterol granuloma (CG) mimicking intraductal papillary–mucinous carcinoma. Although preoperative diagnosis may be difficult, AIP with CG should be considered as a differential diagnosis in pancreatic cysts involving nodular lesions. PubMed, Int J Surg Case Rep. (Also see Autoimmune Pancreatitis)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: